Talphera, Inc. (TLPH) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to the Telfair Virtual Analyst and Investor event. At this time, all attendees are in a listen-only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded and a replay will be made available on the Telfair website following the conclusion of the event. I'd now like to turn the call over to Vince Angotti, Chief Executive Officer at Telfair. Please go ahead. Thank you, Tara. And good morning, everyone, and thank you for joining our event today. I'm excited to be joined by Dr. Shaquille Aslam, Telfer's chief medical officer, and two key experts in continuous renal replacement therapy, who are also principal investigators in our NEFRO CRRT registrational study. Through their experience and expertise, we hope to provide you with a better understanding of CRRT the anticoagulants currently being used during CRRT, and how these experts see Nifamistat potentially filling an unmet need for anticoagulation of the CRRT circuit. Our agenda will specifically include, first, a very brief business update so we can move quickly to our key expert discussion, followed by Q&A and closing remarks. Before we begin, I want to remind listeners that during this call, we'll likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the operations and future results of Taufera. Please refer to our press release in addition to the company's periodic, current, and annual reports filed with the SEC for discussion of the risks associated with such forward-looking statements. These documents can also be found on our website within the investor section. Now for the business update, earlier today we ...